API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or recurrent glioblastoma GBM.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
BDTX-1535, is a EGFR inhibitor (TKI), is under investigation for the treatment of NSCLC harboring intrinsic driver and/or acquired resistance (post-osimertinib) EGFR mutations and glioblastoma multiforme (GBM) with multiple EGFR alterations.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
The net proceeds will be used for the advancement of the Company’s clinical development pipeline, including potential accelerated approval activities for BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in glioblastoma multiforme.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 29, 2023
Details:
The net proceeds will be used for the advancement of the Company’s clinical development pipeline, including potential accelerated approval activities for BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in glioblastoma multiforme.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing December 12, 2022
Details:
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor cell growth in GBM and NSCLC.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
BDTX-1535 is designed as an irreversible, mutant selective, brain-penetrant MasterKey inhibitor of oncogenic mutations of epidermal growth factor receptor expressed in glioblastoma multiforme and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
BDTX-1535 is designed as potent brain-penetrant inhibitor of a spectrum of EGFR mutations expressed in glioblastoma multiforme and NSCLC. BDTX-1535 showed dose-dependent tumor growth inhibition and achieved complete regression without notable impact on body weight.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
BDTX-1535, a CNS penetrant MasterKey inhibitor of common, uncommon and resistant EGFR mutations, demonstrates in vivo efficacy and has potential to treat osimertinib-resistant NSCLC with or without brain metastases.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2021
Details:
Black Diamond Therapeutics will Present pre-clinical data for BDTX-1535 and the biological rationale for a MasterKey approach to treating GBM patients whose tumors harbor allosteric oncogenic mutations in epidermal growth factor receptor.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020